Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

Final Prospectus · 424B4

CapsoVision, Inc.

CVNASDAQEQUITYCurrent

Final Prospectus

Filed Jul 3, 2025Accepted Jul 2, 2025, 8:31 PM EDTCIK 1378325Accession 0001193125-25-155088
Share

Company context

We are a global commercial-stage medical technology company focused on creating diagnostic and screening products to identify abnormalities of the GI tract. We develop advanced imaging and AI technologies in creating such products while maximizing the flexibility, convenience, profitability, and safety of patient care. We are a Delaware company, incorporated in 2005. Our corporate headquarters is located in Saratoga, California.

Current securities

Recent company filings

  1. 4 filingSep 23, 2026
  2. Entry into a Material Definitive AgreementSep 18, 2026
  3. 424B5 filingSep 18, 2026
  4. EFFECT filingAug 21, 2026
  5. 424B5 filingAug 21, 2026

As-filed source

Primary evidence